Palmoplantar pustulosis pipeline: Data Byte

AnaptysBio’s Phase II miss for palmoplantar pustulosis (PPP) may indicate that overactive IL-36 signaling is not the dominant driver of the disease. The news could be a warning for Boehringer Ingelheim GmbH, which has spesolimab (BI 655130), an IL-36R-targeting antibody, in a Phase II trial for PPP.

According to ClinicalTrials.gov, Boehringer’s trial has an estimated completion date of Aug. 5. ...